Trading Halt
Filed with ASX ·
On 6ix: 6ix.com/news/trading-halt-1819
6ix is reading this filing.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Appendix 4C & Quarterly Update
- FDA Type C Feedback, HEALEY trial potentially registrational
- Neurizon Announces Partial Redemption of Convertible Notes
- NIH funds Expanded Access Program for NUZ-001 in ALS
- Neurizon Appoints Chief Executive Officer
Later from Neurizon Therapeutics
- Firm commitments to raise A$4.3m and announcement of SPP
- Redemption of all remaining Obsidian convertible notes
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics